Bendamustine in advanced multiple myeloma previously treated with bortezomid and lenalidomide containing regimen

被引：0
|
作者：
Lehenbauer-Dehm, S. [1 ]
Alex, M. [1 ]
Pecher, G. [1 ]
Blau, I [2 ]
Eucker, J. [1 ]
Possinger, K. [1 ]
Scholz, C. [1 ]
机构：
[1] Charite, D-13353 Berlin, Germany
[2] Charite Campus Benjamin Franklin, Berlin, Germany
来源：
ONKOLOGIE | 2012年 / 35卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：145 / 146
页数：2
相关论文
共 50 条
  • [1] Lenalidomide improves survival in previously treated patients with multiple myeloma
    不详
    ONCOLOGY-NEW YORK, 2006, 20 (01): : 43 - 43
  • [2] Plateau is a prognostic factor of lenalidomide therapy for previously treated multiple myeloma
    Takakuwa, Teruhito
    Ohta, Kensuke
    Nakatani, Eiji
    Ito, Tomoki
    Kaneko, Hitomi
    Fuchida, Shin-Ichi
    Shimura, Yuji
    Yagi, Hideo
    Shibayama, Hirohiko
    Kanda, Junya
    Uchiyama, Hitoji
    Kosugi, Satoru
    Tanaka, Hirokazu
    Kawata, Eri
    Uoshima, Nobuhiko
    Ishikawa, Jun
    Shibano, Masaru
    Karasuno, Takahiro
    Shindo, Maki
    Shimizu, Yoshifumi
    Imada, Kazunori
    Kanakura, Yuzuru
    Kuroda, Junya
    Hino, Masayuki
    Nomura, Shosaku
    Takaori-Kondo, Akifumi
    Shimazaki, Chihiro
    Matsumura, Itaru
    HEMATOLOGICAL ONCOLOGY, 2021, 39 (03) : 349 - 357
  • [3] Bendamustine, thalidomide and dexamethasone is an effective salvage regimen for advanced stage multiple myeloma
    Grey-Davies, E.
    Bosworth, J. L.
    Boyd, K. D.
    Saso, R.
    Chitnavis, D.
    Mercieca, J. E.
    Morgan, G. J.
    Davies, F. E.
    BRITISH JOURNAL OF HAEMATOLOGY, 2011, 153 : 22 - 22
  • [4] Bendamustine, Thalidomide and Dexamethasone is an effective salvage regimen for advanced stage multiple myeloma
    Grey-Davies, Elisabeth
    Bosworth, Jennifer L.
    Boyd, Kevin D.
    Ebdon, Caroline
    Saso, Radovan
    Chitnavis, Dipti
    Mercieca, Jane E.
    Morgan, Gareth J.
    Davies, Faith E.
    BRITISH JOURNAL OF HAEMATOLOGY, 2012, 156 (04) : 552 - 555
  • [5] Successful retreatment with lenalidomide for relapsed and refractory multiple myeloma previously treated with bortezomib, lenalidomide and pomalidomide
    Oka, Satoko
    Ono, Kazuo
    Nohgawa, Masaharu
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2018, 43 (06) : 914 - 917
  • [6] COMPARISONS OF REGIMEN COSTS OF BORTEZOMIB AND LENALIDOMIDE FOR TREATMENT OF ADVANCED, RELAPSED MULTIPLE MYELOMA
    Hornberger, J.
    Rickert, J.
    Dhawan, R.
    Baldesano, D.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 477 - 477
  • [7] POMALIDOMIDE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) PREVIOUSLY TREATED WITH LENALIDOMIDE
    Gomez, Hernando Marta
    Gironella, Merce
    Abella, Eugenia
    Cabezudo, Elena
    Motllo, Cristina
    Garcia, Antoni
    Sarra, Josep
    Mostacedo, Silvia
    Granell, Miquel
    Rosinol, Laura
    HAEMATOLOGICA, 2020, 105 : 13 - 14
  • [8] Long-Term Treatment with Lenalidomide in Previously Treated Subjects with Multiple Myeloma
    Amor, A. A.
    Aguado, B.
    Camara, C.
    Velasco, A.
    Garcia-Escribano, F.
    CLINICAL LYMPHOMA & MYELOMA, 2009, 9 : S68 - S69
  • [9] Activity and toxicity profiles of the combinations bendamustine-lenalidomide-dexamethasone and bendamustine-bortezomib-dexamethasone for advanced stage multiple myeloma
    Mele, Giuseppe
    Spina, Alessandro
    Guaragna, Gianluca
    Giannotta, Angela
    Melpignano, Angela
    Quarta, Gianni
    LEUKEMIA & LYMPHOMA, 2014, 55 (05) : 1191 - 1193
  • [10] Efficacy of Lenalidomide in Patients with Multiple Myeloma Previously Treated by Melphalan-Prednisone and Thalidomide
    Michel, Jessica
    Revuz, Sabine
    Tardy, Stephanie
    Fouquet, Guillemette
    Roussel, Murielle
    Balasanu, Oana
    Bologna, Serge
    Bonmati, Caroline
    Perrot, Aurore
    Ranta, Dana
    Feugier, Pierre
    Attal, Michel
    Leleu, Xavier
    Facon, Thierry
    Hulin, Cyrille
    BLOOD, 2012, 120 (21)
12345